Research Analysts Offer Predictions for DVAX Q1 Earnings

Dynavax Technologies Co. (NASDAQ:DVAX) – Equities research analysts at William Blair lowered their Q1 2025 EPS estimates for Dynavax Technologies in a research report issued to clients and investors on Friday, February 21st. William Blair analyst M. Phipps now expects that the biopharmaceutical company will earn $0.03 per share for the quarter, down from their previous estimate of $0.04. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Dynavax Technologies’ current full-year earnings is $0.32 per share. William Blair also issued estimates for Dynavax Technologies’ Q2 2025 earnings at $0.09 EPS, Q3 2025 earnings at $0.12 EPS, Q4 2025 earnings at $0.04 EPS, FY2025 earnings at $0.28 EPS, Q1 2026 earnings at $0.11 EPS, Q2 2026 earnings at $0.18 EPS, Q3 2026 earnings at $0.21 EPS, Q4 2026 earnings at $0.11 EPS and FY2026 earnings at $0.61 EPS.

A number of other brokerages also recently commented on DVAX. HC Wainwright restated a “buy” rating and issued a $31.00 price objective on shares of Dynavax Technologies in a research report on Friday, February 21st. The Goldman Sachs Group downgraded shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and reduced their price objective for the company from $15.00 to $12.00 in a research report on Tuesday, February 11th. Finally, StockNews.com upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Monday.

Dynavax Technologies Price Performance

Shares of NASDAQ:DVAX opened at $13.41 on Monday. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. The company has a market cap of $1.76 billion, a P/E ratio of 74.50 and a beta of 1.32. Dynavax Technologies has a 52 week low of $9.74 and a 52 week high of $14.05. The company has a 50-day moving average price of $12.83 and a 200 day moving average price of $12.06.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, meeting analysts’ consensus estimates of $0.05. The firm had revenue of $72.03 million during the quarter, compared to the consensus estimate of $72.70 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Deep Track Capital LP increased its holdings in Dynavax Technologies by 42.0% in the fourth quarter. Deep Track Capital LP now owns 17,791,486 shares of the biopharmaceutical company’s stock valued at $227,197,000 after buying an additional 5,265,000 shares in the last quarter. Deerfield Management Company L.P. Series C increased its holdings in Dynavax Technologies by 23,990.1% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 5,193,823 shares of the biopharmaceutical company’s stock valued at $66,325,000 after buying an additional 5,172,263 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in Dynavax Technologies by 4.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 4,067,951 shares of the biopharmaceutical company’s stock valued at $51,948,000 after buying an additional 171,933 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Dynavax Technologies by 1.8% in the fourth quarter. Renaissance Technologies LLC now owns 2,355,278 shares of the biopharmaceutical company’s stock valued at $30,077,000 after buying an additional 41,000 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. increased its holdings in Dynavax Technologies by 34.0% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,918,340 shares of the biopharmaceutical company’s stock valued at $24,497,000 after buying an additional 486,981 shares in the last quarter. 96.96% of the stock is owned by hedge funds and other institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.